Cisplatin: Clinical Trials

876 trials of Cisplatin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

339 completed, 158 unknown, 128 recruiting, 111 active not recruiting. 876 Phase 3, 105 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3876Completed 339, Unknown 158, Recruiting 128, Active not recruiting 111, Terminated 74, Not yet recruiting 36, Withdrawn 26, Enrolling by invitation 2, Suspended 2
Phase 2105Recruiting 25, Completed 22, Unknown 21, Active not recruiting 16, Not yet recruiting 9, Terminated 8, Suspended 2, Enrolling by invitation 1, Withdrawn 1

Follow Cisplatin: new trials by email Literature Review of Cisplatin trials Research Report on Cisplatin

Trials (filtered) newest first · largest first

All 876 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Test Shorter Duration Chemoradiation Therapy Versus Standard Duration Chemoradiation Therapy for Cervical Cancer
Biospecimen Collection, Brachytherapy, Cisplatin - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Phase 3Not yet recruitingNRG Oncology5502027-05-192026-11-10
Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Cisplatin, Carboplatin, Pemetrexed - Advanced NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer
Phase 3Not yet recruitingGoethe University1982027-02-012026-11-17
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer
standard EBRT+Brachytherapy, Cisplatin, Neoadjuvant chemoimmunotherapy - Locally Advanced Cervical Carcinoma
Phase 3Not yet recruitingFujian Cancer Hospital4862027-01-012026-11-16
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
SHR-A1811 Injection, Adebrelimab Injection, Tislelizumab Injection - Non Small Cell Lung Cancer
Phase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.4362026-12-012026-10-26
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
Pembrolizumab, Carboplatin (AUC 5), Cisplatin (75 mg/m²) - Non-Small Cell Lung Cancer
Phase 3Not yet recruitingGerman Cancer Research Center4062026-11-302026-10-16
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
LBL-024 for Injection, Etoposide injection, Cisplatin injection - Advanced Extrapulmonary Neuroendocrine Carcinoma
Phase 3Not yet recruitingNanjing Leads Biolabs Co.,Ltd2802026-11-162026-10-19
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer
Phase 3RecruitingSystImmune Inc.5202026-11-012026-11-18
A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
HS-10370, Adebrelimab, Cisplatin - Carcinoma, Non-Small-Cell Lung
Phase 3Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4482026-10-312026-09-16
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
ASKC202, ASKC202 placebo, osimertinib placebo - EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3Not yet recruitingJiangsu Aosaikang Pharmaceutical Co., Ltd.4252026-10-302026-10-27
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer
QLC5508, QL2107, Tislelizumab - Extensive-stage Small Cell Lung Cancer
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.5562026-10-272026-10-30
Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC
HS-10504, platinum-based doublet chemotherapy (Pemetrexed and Cisplatin/Carboplatin) - Advanced or Metastatic NSCLC
Phase 3RecruitingJiangsu Hansoh Pharmaceutical Co., Ltd.2062026-10-232026-11-02
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer
Phase 3RecruitingMerck Sharp & Dohme LLC4002026-10-232026-11-16
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer
Phase 2 / Phase 3RecruitingSichuan Baili Pharmaceutical Co., Ltd.1662026-10-212026-11-12
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC)
Phase 3Not yet recruitingSuzhou Zelgen Biopharmaceuticals Co.,Ltd4402026-10-012026-09-22
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC)
Phase 3RecruitingFirst Affiliated Hospital of Guangxi Medical University2662026-09-082026-11-09
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer
Phase 3RecruitingBristol-Myers Squibb8502026-09-082026-11-10
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
Gemcitabine, Cisplatin, Tislelizumab - Intrahepatic Cholangiocarcinoma (Icc)
Phase 3Not yet recruitingZhejiang Cancer Hospital1402026-09-012026-10-26
A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)
BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC)
Phase 3Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.4042026-09-012026-09-15
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
zoldonrasib, Placebo, pembrolizumab - NSCLC, Non-small Cell Lung Cancer
Phase 3RecruitingRevolution Medicines, Inc.4302026-08-142026-11-04

Showing 20 of 876. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (178)  ·  Lung Neoplasms (63)  ·  Uterine Cervical Neoplasms (59)  ·  Nasopharyngeal Carcinoma (58)  ·  Squamous Cell Carcinoma of Head and Neck (58)  ·  Head and Neck Neoplasms (52)  ·  Stomach Neoplasms (40)  ·  Esophageal Neoplasms (38)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (38)  ·  Esophageal Squamous Cell Carcinoma (29)  ·  Urinary Bladder Neoplasms (29)  ·  Small Cell Lung Carcinoma (23)  ·  Cholangiocarcinoma (20)  ·  Ovarian Neoplasms (19)  ·  Carcinoma (17)

Sponsors

Sun Yat-sen University (48)  ·  Merck Sharp & Dohme LLC (45)  ·  AstraZeneca (31)  ·  National Cancer Institute (NCI) (28)  ·  Children's Oncology Group (23)  ·  European Organisation for Research and Treatment of Cancer - EORTC (22)  ·  Hoffmann-La Roche (21)  ·  Bristol-Myers Squibb (20)  ·  Radiation Therapy Oncology Group (17)  ·  Gynecologic Oncology Group (16)  ·  Eli Lilly and Company (13)  ·  Alliance for Clinical Trials in Oncology (11)  ·  Fudan University (11)  ·  UNICANCER (10)  ·  Sanofi (9)

Countries

China (336)  ·  United States (332)  ·  France (203)  ·  Italy (187)  ·  Canada (185)  ·  United Kingdom (181)  ·  Spain (178)  ·  Germany (174)  ·  South Korea (167)  ·  Australia (155)  ·  Japan (146)  ·  Poland (139)  ·  Taiwan (138)  ·  Belgium (136)  ·  Brazil (127)

Top investigators

Jun Ma, M.D. (7)  ·  Cesare Gridelli, M.D. (6)  ·  Francesco Perrone, M.D., Ph.D. (4)  ·  Ciro Gallo, M.D., Ph.D (3)  ·  Ciro Gallo, M.D., Ph.D. (3)

Results publications

PMID 37139963, PMID 22689675, PMID 28837405, PMID 29584545, PMID 31150573, PMID 33358660, PMID 40501401, PMID 41343184, PMID 21444871, PMID 21840137, PMID 22551107, PMID 24982463, PMID 25057165, PMID 25624439, PMID 27567280, PMID 29924955, PMID 30213452, PMID 30548235, PMID 30633128, PMID 31401903, PMID 31420360, PMID 33337539, PMID 33492986, PMID 33661301, PMID 33684371, PMID 35997729, PMID 37158938, PMID 37419867, PMID 37465924, PMID 37505794, PMID 37699333, PMID 38383458, PMID 38642841, PMID 39230120, PMID 39369790, PMID 40311309, PMID 40373876, PMID 40532178, PMID 40966692, PMID 41747891, PMID 41887529, PMID 42176183, PMID 42579028, PMID 10481771, PMID 10882162, PMID 11181777, PMID 11391598, PMID 11464889, PMID 11560968, PMID 11762335

NIH funding

2023 (29), 2018 (18), U10CA180868 (18), U10CA180886 (17), 2019 (16), U10CA098543 (16), 2017 (15), 2016 (12), U10CA180820 (12), 2014 (11), 2015 (10), U10CA027469 (9), U10CA032102 (8), U10CA031946 (7), 2025 (5)